Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XTL BiopharmaceuticalsXTLB +1.20%28 1-Year Share Buyback Ratio is -7.40 as of Dec. 2025. GuruFocus rates XTLB with a GF Score™ of 28/100. The stock has 4 warning signs investors should review. Among 1,109 Biotechnology companies, XTL Biopharmaceuticals ranks better than 60.5% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. XTL Biopharmaceuticals's current 1-Year Share Buyback Ratio was -7.40%.
XTLB's 1-Year Share Buyback Ratio is ranked better than 60.5% of 1109
companies
in the Biotechnology industry
Industry Median: -14.5
vs XTLB: -7.40
XTL Biopharmaceuticals (NAS:XTLB) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
XTL Biopharmaceuticals 1-Year Share Buyback Ratio Related Terms
XTLB vs VRTX, REGN, MRNA: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, XTL Biopharmaceuticals's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -7.40 mean?
XTL Biopharmaceuticals (XTLB) has a 1-Year Share Buyback Ratio of -7.40 as of Dec. 2025. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for XTL Biopharmaceuticals and its competitors. According to the industry distribution chart, XTL Biopharmaceuticals ranks #438 out of 1109 companies in the Biotechnology industry, placing it in the top 39.5%.
Is XTL Biopharmaceuticals' 1-Year Share Buyback Ratio too high?
XTL Biopharmaceuticals' current 1-Year Share Buyback Ratio is -7.40. Based on the distribution chart, XTL Biopharmaceuticals ranks #438 out of 1109 companies in the Biotechnology industry, which is above the industry midpoint. Overall, XTL Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' 1-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #438 out of 1109 companies for 1-Year Share Buyback Ratio. This puts XTL Biopharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current 1-Year Share Buyback Ratio is -7.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current 1-Year Share Buyback Ratio of -7.40. The current 1-Year Share Buyback Ratio is -7.40. XTL Biopharmaceuticals' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current 1-Year Share Buyback Ratio is -7.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
28GF Score
Get the complete analysis for XTLB
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
